You just read:

Azevan Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of SRX246 in Intermittent Explosive Disorder

News provided by

Azevan Pharmaceuticals, Inc.

May 09, 2016, 10:39 ET